MedTrace Logo

Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon

NCT00226408 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 600

Last updated 2006-06-21

No results posted yet for this study

Summary

The study protocol is being conducted to compare intermittent high-dose i.v. administation of interferon alpha-2b with the standard high-dose treatment by Kirkwood with distant metastasis free survival (DMFI) as a primary endpoint.

Conditions

  • Adjuvant
  • Stage III Malignant Melanoma
  • Interferon Alpha
  • Therapy

Interventions

DRUG

Interferon-alpha-2b

Sponsors & Collaborators

  • Dermatologic Cooperative Oncology Group

    lead OTHER

Principal Investigators

  • Peter Mohr, MD · Elbeklinikum, Buxtehude, Germany

  • Peter von Wussow, MD · 30159 Hannover,Georgstr.46

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-11-30
Completion
2005-09-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00226408 on ClinicalTrials.gov